It interferes with functional NF-κB activation in different carcinoma cell lines (Valentine et al., 2010) and it can contribute to the development of EBV-associated tumors and their progression by activating AP-1 and signal transducer and activator of transcription 1 (STAT1) (O’Neil et al., 2008) and inhibiting TGF-β1 (Wood et al., 2007; Flavell et al., 2008). Here, STAT1 is linked to carcinoma.